Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.20    -5.80 (-5.32%)
Bid:
103.00
Ask:
104.20
Spread: 1.20 (1.165%)
Market Cap: £169.19m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

9 Nov 2016 07:00

RNS Number : 6789O
Synthomer PLC
09 November 2016
 

 

November 9th 2016

Synthomer plc

Q3 Trading update

Positive performance and Full Year 2016 guidance maintained

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th, 2016.

Trading

Europe and North America

Europe and North America has continued to trade well, in line with our expectations and consistent with the positive trends experienced through H1 2016. Q3 reported volumes were in line with last year whilst reported unit margins for the quarter were ahead of Q3 2015 and Q2 2016. Accordingly, with the exception of Paper latex, gross margins across all businesses were stronger than last year. This performance reflects the improved trading environment as well as the Group's focus on efficiency, new product initiatives, strengthened procurement function and investment in business development activities.

Asia and Rest of World

Asia and Rest of World has continued to trade in line with our expectations, with the competitive dynamics in our Asian Nitrile business evolving broadly as expected following the introduction of additional industry capacity.

Reported Asian volumes were marginally lower than last year but sequentially higher than Q2 2016, largely driven by increased volumes in the Asian Nitrile business. As expected, the market environment has led to overall unit margins softening from the highs seen in H2 2015 and H1 2016. Whilst the competitive dynamics in our Asian Nitrile business are continuing to evolve, this downward price pressure has not been as marked as the Group experienced in previous years. We continue to expect full year volumes and margins for this business to be similar to FY 2015.

Hexion PAC

The integration of Hexion PAC is well underway and progressing to plan. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

Foreign currency

The Group has continued to benefit from the translation effect of the ongoing weakness of sterling. Average YTD FX rates are €1.24 and $1.38 which, if unchanged for the remainder of the year, would provide a translational benefit of approximately £10m for the full year.

Financial Position

The Group has generated strong cash flows in Q3, benefitting from Malaysian land sale and South African business sale receipts of £21m and £13m respectively. Net debt has reduced from £215m at 30 June to £159m at 30 September 2016.

The Group balance sheet remains strong with net debt/EBITDA ratio at circa 1.1x.

Outlook

The Board's expectations for Full Year 2016 remain unchanged from the interim results in August. Looking forward, the outlook in 2017 also remains consistent with our previous expectations underpinned by resilient trading in Europe despite a challenging macroeconomic environment, the Asian Nitrile market continuing to evolve broadly in line with our expectations and the ongoing integration of Hexion PAC.

 

Capital Markets Day

Synthomer plc will be hosting a Capital Markets Day for analysts and investors on Thursday December 1st. Senior members of Synthomer's management team will provide an update on strategy as well as present on the Group's two core divisions and R&D and innovation capabilities.

-ENDS-

ENQUIRIES:

Calum MacLean, Chief Executive Officer

Charles Armitstead

Stephen Bennett, Chief Financial Officer

Teneo Blue Rubicon

Tel: + 44 1279 436211

Tel: + 44 207 260 2700

 

 

The Company will hold a conference call for investors and analysts at 0800 GMT today. 

Please dial +44 (0) 808 2370030 entering conference ID: 31555005# to gain access to the call.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBPBLTMBTMBBF
Date   Source Headline
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration
13th Feb 20257:00 amRNSHolding(s) in Company
28th Jan 202510:30 amRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSWinter trading statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.